Abstract
Olanzapine was shown to be oxidized to a reactive intermediate by HOCl, which is the major oxidant produced by activated neutrophils. A mass spectrum obtained using a flow system in which the reactants were fed into a mixing chamber and the products flowed directly into a mass spectrometer revealed a reactive intermediate atm/z 311. This is 2 mass units less than the protonated molecular ion of parent olanzapine and suggests that the reactive intermediate is a nitrenium ion. The reactive intermediate could be trapped with glutathione or N-acetylcysteine to produce two conjugates. These data are analogous to results we reported previously with the structurally related atypical antipsychotic agent clozapine. However, the clozapine and olanzapine reactive metabolites showed differences in their ability to cause toxicity to human neutrophils. Toxicity to neutrophils was observed only at high concentrations of clozapine (>50 μm) when HOCl was used to generate reactive metabolite. In contrast, concentration-dependent toxicity (p < 0.05) was observed when neutrophils were incubated with clozapine (0–20 μm) and H2O2 to generate clozapine reactive metabolite. No toxicity was observed with clozapine alone (at concentrations of > 50 μm). Similar results were observed in monocytes and HL-60 cells. Olanzapine reactive metabolite only seemed to cause slight toxicity at the highest concentrations tested (20 μm), even when the reactive metabolite was generated using H2O2. Neutrophils from two patients with a history of clozapine-induced agranulocytosis seemed to be more sensitive to the toxic effects of the clozapine reactive metabolite; however, the numbers are too small to draw any definite conclusions.
Footnotes
-
Send reprint requests to: Professor Jack Uetrecht, Faculty of Pharmacy, 19 Russell Street, University of Toronto, Toronto, Ontario M5S 2S2, Canada. E-mail: jack.uetrecht{at}utoronto.ca
-
This work was supported by Grant MT-13478 from the Medical Research Council of Canada. I.G. was a recipient of a Postdoctoral Fellowship from the Pharmaceutical Manufacturers Association of Canada and the Medical Research Council of Canada.
- Abbreviations:
- MPO
- myeloperoxidase
- GSH
- glutathione
- HBSS
- Hanks’ balanced salt solution (without phenol red)
- NAC
- N-acetylcysteine
- LC
- liquid chromatography
- MS
- mass spectometry
- HPLC
- high performance liquid chromatography
- PBS
- phosphate-buffered saline
- Received December 19, 1997.
- Accepted February 24, 1998.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|